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Regulating the effects of GPR21, a 
novel target for type 2 diabetes
Siobhán Leonard1, Gemma K. Kinsella1,†, Elisa Benetti2 & John B. C. Findlay1
Type 2 diabetes is a chronic metabolic disorder primarily caused by insulin resistance to which obesity 
is a major contributor. Expression levels of an orphan G protein-coupled receptor (GPCR), GPR21, 
demonstrated a trend towards a significant increase in the epididymal fat pads of wild type high fat 
high sugar (HFHS)-fed mice. To gain further insight into the potential role this novel target may play 
in the development of obesity-associated type 2 diabetes, the signalling capabilities of the receptor 
were investigated. Overexpression studies in HEK293T cells revealed GPR21 to be a constitutively 
active receptor, which couples to Gαq type G proteins leading to the activation of mitogen activated 
protein kinases (MAPKs). Overexpression of GPR21 in vitro also markedly attenuated insulin signalling. 
Interestingly, the effect of GPR21 on the MAPKs and insulin signalling was reduced in the presence of 
serum, inferring the possibility of a native inhibitory ligand. Homology modelling and ligand docking 
studies led to the identification of a novel compound that inhibited GPR21 activity. Its effects offer 
potential as an anti-diabetic pharmacological strategy as it was found to counteract the influence of 
GPR21 on the insulin signalling pathway.
Type 2 diabetes is primarily caused by a systemic insulin resistant state provoked by increasing viseral adipose tis-
sue that triggers chronic, low-grade inflammation, which negatively impacts on the insulin signalling pathway1,2. 
The rising incidence of type 2 diabetes, along with the limitations of current treatment regimes, urge the need 
for innovative, effective strategies to prevent the development and progression of this disease. G protein-coupled 
receptors (GPCRs), the largest protein superfamily in the genome, represent a rich source of drug targets as they 
readily convey external signals to the internal environment of the cell: approximately 30–40% of marketed drugs 
target these versatile receptors3.
Analysis of the G protein to which a GPCR couples to amplify signal potential is key to understanding the 
activity and downstream consequences of receptor activation, as well as providing a means to assess the functional 
impact of any ligands postulated to bind to the receptor. Selective GPCR coupling to Gα q subtype G proteins leads 
to the activation of phospholipase C (PLC)4, which cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into 
the secondary messengers, diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). The membrane bound 
DAG activates protein kinase C (PKC), whereas, the soluble IP3 binds to its receptor in the endoplasmic reticu-
lum triggering the release of Ca2+ 5. Downstream of this, a wide range of intracellular pathways can be activated, 
including the mitogen activated protein kinase (MAPK) cascade6. The MAPK family comprises three members; 
extracellular-signal-regulated protein kinase (Erk), p38, and c-Jun NH2-terminal kinase (JNK), which play cru-
cial roles in cell proliferation, oncogenesis, differentiation, inflammation, stress responses and cell migration7,8. 
Notably, JNK is recognised as a major contributor to insulin resistance as it induces the phosphorylation of insu-
lin receptor substrate 1 (IRS1) at Ser307. This prevents insulin-stimulated tyrosine phosphorylation of the protein, 
thus attenuating the insulin signalling pathway9.
We have observed an increase in the expression levels of an orphan GPCR, GPR21, in the adipose tissue of 
high fat high sugar (HFHS)-fed mice. Although this increase did not reach a statistically significant level, GPR21 
may represent a novel means by which the type 2 diabetic phenotype could be targeted as this GPCR has been 
suggested to couple with the Gα q subtype G proteins, Gα q10 and Gα 15/1611. Advances in homology modelling and 
ligand docking studies have greatly facilitated the development of targeted therapies towards orphan GPCRs12. As 
the structure of GPR21 remains unknown, these techniques were employed to identify potential small molecules 
capable of binding to and regulating the effects of this receptor.
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This work provides an analysis of GPR21-induced signal transduction, yielding an insight into the mecha-
nisms by which this receptor could exert an effect in the type 2 diabetic phenotype and thus may represent an 
opportunity for a new therapeutic strategy. The observed constitutive activity of GPR21, which promotes MAPK 
activation and negatively impacts on the insulin signalling pathway, may be regulated by a native ligand present 
in serum. Furthermore, a novel compound designed to bind to GPR21 has been found to protect against the 
observed effects of the receptor on the insulin signalling pathway.
Results
GPR21 is a constitutively active receptor signalling through Gα15/16. Analysis of the epididymal 
fat pads of wild type C57BL/6J mice, a meaningful indicator of obesity-related diabetes, revealed an increase in 
GPR21 expression, which trended towards significance, in HFHS-fed mice (Fig. 1a), with a concurrent elevation 
in the macrophage marker F4/80 (Fig. 1b). Following on from this, an investigation into the G protein to which 
GPR21 is believed to couple was undertaken to give further insight into the functional consequence of a potential 
increase in expression. Analysis of inositol-1-phosphate (IP1) production was used as a surrogate of the transient 
secondary messenger IP3 to monitor activation of the Gα q pathway13. The orphan receptor, GPR21, demonstrated 
constitutive activity when overexpressed in HEK293T cells as indicated by an increase in endogenous IP1 in the 
absence of a ligand (Fig. 1d). To determine the spectrum of Gα q proteins GPR21 is capable of signalling through, 
HEK293T cells were co-transfected with cDNAs of the α -subunits of the Gq family, Gα q, Gα 15/16 and Gα 14. When 
expressed with the empty vector, pCMV6-Entry, all Gα q subtypes led to an increase in basal IP1 levels. When 
coupled with GPR21, an increase in IP1 production was observed in HEK293T cells overexpressing Gα q. This 
indication of GPR21 constitutive activity further increased when the receptor was coupled with Gα 15/16. Gα 14 did 
not appear to influence GPR21-induced production of IP1. The PLC inhibitor, U73122, led to a dose-dependent 
decrease in IP1 production in HEK293T cells overexpressing both GPR21 alone (Fig. 1e) and coupled with Gα 15/16 
(Fig. 1f), reinforcing the pathway involved.
Overexpression of GPR21 leads to activation of the MAPKs and negatively impacts on the insu-
lin signalling pathway. Downstream of GPR21-mediated PLC activation meaningful effects on PKCδ and 
Figure 1. Analysis of GPR21 expression and activity. Epididymal fat pads of control and HFHS-fed C57BL/6J 
mice were lysed, proteins separated by SDS-PAGE and expression of (a) GPR21 and (b) the macrophage marker, 
F4/80, evaluated by Western blotting. Representative Western blots are shown along with relative densities, 
determined using Image J software, presented as mean ± SEM, n = 9. Using the unpaired Student’s t-test a 
significant increase in F4/80 expression was observed at p < 0.01**. (c) Representative Coomassie stained gel 
used to confirm equal loading of protein extracted from murine epididymal fat pads. (d) A FRET-based IP-one 
assay was employed to assess the activity of GPR21 in transiently transfected HEK293T cells when coupled with 
the Gα q G protein subtypes, Gα q, Gα 15/16 or Gα 14. HEK293T cells were also transfected with the empty vector, 
pCMV6-Entry. Data presented as mean ± SEM are representative of three independent experiments performed 
in triplicate each time. One-way ANOVA with a post-hoc Tukey test denotes a significant increase in GPR21-
induced IP1 production at p < 0.05* and p < 0.001***. As Gα q stimulation induces PLC activation to trigger the 
inositol cascade, the effect of the PLC inhibitor, U73122, on IP1 production was also assessed in HEK293T cells 
transiently transfected with (e) pCMV6-Entry or GPR21 and (f) pCMV6-Entry or GPR21 coupled with Gα 15/16. 
GraphPad Prism® 5 software was used to generate a non-linear sigmoidal dose response curve in response 
to U73122. Data presented as mean ± SEM are representative of two independent experiments performed in 
triplicate each time.
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the MAPKs were observed. Overexpression of GPR21 led to a considerable increase in the phosphorylation of 
PKCδ , Erk, p38 and JNK, an effect that could be attenuated with 50 nM of the PKC inhibitor GF109203X (Fig. 2a). 
Incubation with 10 μ M U73122 also reduced the impact of GPR21 on the MAPKs, the effect on JNK being sim-
ilar to that of the JNK inhibitor, SP600125 (Fig. 2b). The influence of GPR21 overexpression on the MAPKs 
was markedly reduced in the presence of serum (Fig. 2c), suggesting the existence of an inhibitory ligand for 
Figure 2. Analysis of the effect of GPR21 on the MAPKs, insulin signalling and glucose uptake. (a) HEK293T 
cells transiently transfected with pCMV6-Entry or GPR21 were incubated with 50 nM GF109203X or an equal 
volume of the vehicle control, DMSO, for 16 h in serum free medium. (b) HEK293T cells transiently transfected 
with pCMV6-Entry or GPR21 were incubated with 10 μ M U73122, 10 μ M SP600125 or an equal volume of 
DMSO in serum free medium for 24 h. (c) HEK293T cells transiently transfected with pCMV6-Entry or GPR21 
and (d) pCMV6-Entry or GPR21 coupled with Gα 15/16, were incubated for 24 h in the presence or absence of 
10% (v/v) FBS. Cells were lysed and subjected to SDS-PAGE followed by immunoblotting with antibodies against 
phospho-PKCδ Thr505, phospho-Erk Thr202/Tyr204, Erk, phospho-p38 Thr180/Tyr182, p38, phospho-JNK Thr183/
Tyr185, JNK, myc and β -actin. Western blots are representative of two separate experiments. (e) HEK293T cells 
transiently transfected with pCMV6-Entry or GPR21 and (f) pCMV6-Entry or GPR21 coupled with Gα 15/16, were 
incubated for 24 h in the presence or absence of 10% (v/v) FBS, then stimulated with 100 nM insulin for 1 h. Cells 
were lysed and subjected to SDS-PAGE followed by immunoblotting with antibodies against phospho-Insulin 
Receptor β Tyr1150/1151, Insulin Receptor β , phospho-IRS1 Tyr612, IRS1, phospho-Akt Ser473, Akt, phospho-AS160 
Thr642, phospho-AS160 Ser588, AS160, myc and β -actin. Western blots are representative of three separate 
experiments. Alternatively, the consequential effect on glucose uptake was established by measuring cellular 
levels of [3H]-2-deoxyglucose in cells transiently transfected with (g) pCMV6-Entry or GPR21 and (h) pCMV6-
Entry or GPR21 coupled with Gα 15/16. Data presented as mean ± SEM are representative of two independent 
experiments performed in triplicate. One-way ANOVA with a post-hoc Tukey test conveys a significant increase 
in glucose uptake at p < 0.05* and p < 0.01** . A significant decrease in glucose uptake is denoted at p < 0.05#, 
p < 0.01## and p < 0.001###.
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this constitutively active receptor. When coupled with Gα 15/16 (Fig. 2d), GPR21 overexpression again led to an 
increase in the phosphorylation of Erk, p38 and JNK. However, in the presence of serum, a minimal reduction in 
phosphorylation was seen.
As overexpression of GPR21 caused a marked increase in JNK phosphorylation, the influence of the recep-
tor on the insulin signalling pathway was assessed. HEK293T cells overexpressing GPR21 did not respond to 
insulin-induced stimulation of its receptor, a result that was somewhat reduced in the presence of serum (Fig. 2e). 
Further down the pathway, GPR21 overexpression impeded the phosphorylation of IRS1, Akt and AS160 in 
the presence and absence of insulin. This outcome was again reduced when cells were incubated with medium 
containing serum. A related result was observed when GPR21 was coupled with Gα 15/16 (Fig. 2f), although the 
impact of serum was modest. As a consequence of an attenuated insulin signalling pathway, GPR21 also caused 
a significant decrease in glucose uptake, which partially recovered in the presence of serum (Fig. 2g). When 
co-expressed with Gα 15/16 a similar trend was observed (Fig. 2h). The influence of GPR21 on the insulin signalling 
pathway is not limited to HEK293T cells, as this effect can also be seen in CHO cells overexpressing the receptor 
(see Supplementary Fig. S1).
A novel compound protects against the effects of GPR21. Virtual screening of an in house model 
of GPR21 identified 11 compounds with the potential to bind to GPR21. One compound, GRA2, appeared to 
act as an inverse agonist of the orphan receptor. This novel compound decreased IP1 production in cells over-
expressing GPR21 (Fig. 3a), a finding more pronounced when the receptor was coupled with Gα 15/16 (Fig. 3b). 
In the presence of GRA2, GPR21 had no effect on insulin-stimulated phosphorylation of its receptor, whereas 
GPR21 overexpression diminished the effect of insulin in cells incubated with the DMSO control (Fig. 3c). GRA2 
counteracted the GPR21 effect on IRS1, and the phosphorylation of Akt and of AS160 at two residues critical 
to facilitate the translocation of the glucose transporter, GLUT4, also improved, although, to a lesser extent. In 
addition to this, HEK293T cells transfected with pCMV6-Entry demonstrated a slight response to GRA2, in that 
phosphorylation of the components of the insulin signalling cascade increased somewhat, potentially due to a 
low level of endogenous receptor. A similar response was seen in cells co-transfected with GPR21 and Gα 15/16 
(Fig. 3d). Treatment of HEK293T cells with 10 μ M GRA2 for 24 h did not significantly alter glucose uptake in cells 
transfected with the empty vector. However, insulin-induced glucose uptake improved in cells overexpressing 
GPR21 when compared to the vehicle control, DMSO (Fig. 3e). A similar result was observed when GPR21 was 
coupled with Gα 15/16 (Fig. 3f).
Discussion
Overexpression of GPR21 in vitro has assisted in elucidating the underlying mechanisms by which this receptor 
may contribute to the development of insulin resistance and type 2 diabetes.
Analysis of IP1 production, a stable downstream metabolite of IP3 that accumulates upon Gα q receptor activa-
tion, suggested that GPR21, overexpressed in HEK293T cells, could couple to and activate Gα q in the absence of 
a ligand, a hallmark of constitutive activity. Co-expression with the specific members of the Gα q family revealed 
a functional interaction between GPR21 and Gα 15/16, thereby facilitating PLC signalling. The addition of the 
PLC inhibitor, U73122, inhibited GPR21-induced production of IP1, confirming the selectivity of GPR21 on 
this signalling cascade. Furthermore, GPR21 was found to increase the phosphorylation of PKCδ , leading to the 
activation of the MAPKs, Erk, p38 and JNK, an effect that was also found to be dependent on PLC signalling. In 
the presence of medium containing 10% (v/v) FBS, the effect of GPR21 on MAPK activation was less significant, 
particularly in cells overexpressing the receptor alone, indicating the possibility of an endogenous regulatory 
ligand for GPR21 in serum. The inhibitory influence of this potential ligand on GPR21 activity was also seen 
on the insulin signalling pathway and associated glucose uptake. The action of the ligand may be to inhibit the 
GPR21-induced increase in JNK activity. The possibility of an endogenous ligand suggests that the proposed 
effect of GPR21 may be tightly regulated under normal physiological conditions and may only become deleteri-
ous in cases where this signalling pathway is altered.
In addition to these observations, GPR21 knockout studies have generated data that implicate the receptor 
in the development of the type 2 diabetic phenotype14,15. Mice lacking this GPCR, fed on a high fat diet (HFD), 
demonstrate increased insulin sensitivity, improved glucose tolerance and a reduction in pro-inflammatory 
markers, when compared to wild type littermates. Osborn and colleagues14 proposed GPR21 to have a role in 
co-ordinating macrophage pro-inflammatory activity, an effect which could be attributed to the effect of the 
receptor on JNK activation, as increased expression of this MAPK has been reported to promote HFD-induced 
accumulation of macrophages in adipose tissue16.
Given the influence of GPR21 on insulin signalling, a molecule that blocks its constitutive activity in a similar 
manner to the prospective native ligand could be a novel and powerful pharmacological strategy for the treatment 
of type 2 diabetes. Constitutively active orphan GPCRs, such as GPR21 provide a direct route to drug discovery 
as their functionality can be understood without the need to identify endogenous ligands17. A novel compound, 
GRA2, designed through in silico screening to bind to GPR21, demonstrated potential as an inverse agonist of 
the orphan receptor as it reduced the accumulation of IP1 in HEK293T cells overexpressing the receptor alone 
and more evidently with Gα 15/16. As a consequence of reduced receptor activity, the signalling capabilities of 
insulin improved in cells overexpressing GPR21 with and without Gα 15/16, resulting in a meaningful restoration 
of insulin-induced glucose uptake. Cells transfected with the empty vector also displayed modestly enhanced 
phosphorylation of the proteins involved in the insulin signalling cascade in response to GRA2. This may be as a 
consequence of the low level of endogenous GPR21 expressed in HEK293T cells. Structure-activity relationship 
studies based on this compound should yield higher affinity agents capable of exerting a more powerful effect 
through GPR21.
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This work demonstrates the potential role GPR21 may play in the development of type 2 diabetes (Fig. 4). 
Obesity-induced type 2 diabetes may be associated with the dysregulation of GPR21 through an increase in 
receptor expression, an increase in an endogenous agonist or a reduction in an inverse agonist, leading to the 
stimulation of the MAPKs, which contribute to the inhibitory influences of GPR21. Targeting GPR21 with an 
inverse agonist such as the one identified in this study could curtail some of the many facets contributing to the 
development of insulin resistance and type 2 diabetes.
Figure 3. Analysis of the effect of a novel compound in HEK293T cells overexpressing GPR21. The direct 
effect of GRA2 on IP1 production was assessed using a functional FRET-based IP-one assay with HEK293T cells 
transiently transfected with (a) pCMV6-Entry or GPR21 and (b) pCMV6-Entry or GPR21 coupled with Gα 15/16. 
To analyse the downstream effects of GRA2 on regulating the impact of GPR21 on the insulin signalling pathway, 
HEK293T cells overexpressing (c) pCMV6-Entry or GPR21 and (d) pCMV6-Entry or GPR21 coupled with Gα 15/16 
were incubated with 10 μ M GRA2 or an equal volume of the vehicle control in serum free medium for 24 h followed 
by a 1 h stimulation with 100 nM insulin. Cells were lysed and subjected to SDS-PAGE followed by immunoblotting 
with antibodies against phospho-Insulin Receptor β Tyr1150/1151, Insulin Receptor β , phospho-IRS1 Tyr612, IRS1, 
phospho-Akt Ser473, Akt, phospho-AS160 Thr642, phospho-AS160 Ser588, AS160, myc and β -actin. Western blots 
are representative of two separate experiments. To establish the direct impact on glucose uptake, incorporation of 
[3H]-2-deoxyglucose was evaluated via scintillation counting of solubilised cells overexpressing (e) pCMV6-Entry 
or GPR21 and (f) pCMV6-Entry or GPR21 coupled with Gα 15/16. Data presented as mean ± SEM are representative 
of two independent experiments performed in triplicate. A significant increase in glucose uptake was observed at 
p < 0.05* , p < 0.01** and p < 0.001*** .
www.nature.com/scientificreports/
6Scientific RepoRts | 6:27002 | DOI: 10.1038/srep27002
Methods
Animals. Male C57BL/6J mice, aged 4 weeks (n = 18 provided by Charles River, Calco, Lecco, Italy) were 
housed in a temperature-controlled environment with a 12 h light/dark cycle. The animals were maintained on 
a pellet diet for 1 week, then randomly divided into two groups: normal diet (control, n = 9) and a high fat 
high sugar diet (HFHS, n = 9) for 16 weeks. The HFHS diet contained 45% kcal fat, 35% kcal carbohydrates and 
20% kcal protein (D12451, ssniff Spezialdiäten GmbH, Germany). The procedures followed in this study were 
approved by the Animal Use and Care Committee of the University of Turin and subsequently by the ethics com-
mittee of the National University of Ireland, Maynooth (BSRESC-2014-008). Protocols were in accordance with 
the European Directive 2010/63/EU on the protection of animals used for scientific purposes.
Cell culture, transfection and treatment. HEK293T cells were maintained in complete medium 
(high glucose Dulbecco’s Modified Eagle’s Medium (DMEM) containing 2 mM L-glutamine and 100 μ g/ml 
penicillin-streptomycin) supplemented with 10% (v/v) foetal bovine serum (FBS) (Sigma), at 37 °C in a humid-
ified 5% CO2 atmosphere. Cells were transfected with 2 μ g human GPR21 containing a myc-tag incorporated 
into the C-terminus, or the empty vector, pCMV6-Entry (OriGene Technologies), with Lipofectamine® 2000 
(Invitrogen) according to the manufacturer’s protocols. When co-transfecting with cDNAs corresponding to the 
G protein α -subunits, Gα q, Gα 15/16 and Gα 14 (cDNA Resource Centre), 1 μ g of each plasmid was used. Cells were 
incubated for 24 h at 37 °C to allow incorporation of the plasmid DNA. To determine the influence of serum on 
GPR21 activity, cells were incubated for a further 24 h with fresh complete medium ± 10% (v/v) FBS. Treatment 
with compounds (GF109203X, U73122 and SP600125, Sigma) was carried out in serum free complete medium. 
To assess the effect of GPR21 on insulin signalling, HEK293T cells were stimulated with 100 nM insulin (Sigma) 
in Kreb’s Ringer Buffer (KRB); 136 mM NaCl, 20 mM HEPES, 4.7 mM KCl, 1 mM MgSO4, 1 mM CaCl2, 4.05 mM 
Na2HPO4, 0.95 mM NaH2PO4, pH 7.4, containing 5 mM glucose for 1 h at 37 °C.
Inositol Phosphate one (IP-one) Homogenous Time Resolved Fluorescence (HTRF) 
assay. Cellular IP1 levels were measured using an IP-one HTRF assay kit (Cisbio)13. Briefly, subconfluent 
cells were detached from the cell culture dish by trypsinisation and resuspended in the appropriate volume of 
the assay stimulation buffer (10 mM HEPES, 1 mM CaCl2, 0.5 mM MgCl2, 4.2 mM KCl, 146 mM NaCl, 5.5 mM 
glucose, 50 mM LiCl, pH 7.4) warmed to 37 °C, to achieve a concentration of 6 × 106 cells/ml. The cell suspension 
was added to a white half-volume 384 well plate (Greiner) along with the compound to be tested and incubated at 
37 °C for 2 h. IP-one lysis buffer containing 5% IP-one-d2 conjugate was added to the appropriate wells, followed 
by 5% anti-IP-one cryptate Tb conjugate. Samples were incubated in the dark for 1 h at room temperature. The 
plate was read on BMG labtech plate reader with an excitation at 340 nm and emission at 615 nm and 665 nm 
respectively. The fluorescence resonance energy transfer (FRET) ratios (665 nm/615 nm) were converted to IP1 
concentrations by interpolating values from an IP1 standard curve.
Preparation of lysates and Western blot analyses. Frozen murine epididymal fat pads were homog-
enised in ice-cold lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 50 mM NaF, 1 mM EGTA, 1.5 mM MgCl2, 
2 mM Na3VO4, 10% (v/v) glycerol,   mM Na4P2O7, 1 mM PMSF, 1X SigmaFAST protease inhibitor cocktail and 
1% (v/v) Triton x-100) at a ratio of 1:5 (w:v) using a handheld T10 Basic Homogeniser (IKA). Cells were washed 
three times with ice-cold phosphate buffered saline (PBS) then resuspended in lysis buffer. Crude extracts were 
incubated for 1 h at 4 °C with constant agitation. Samples were centrifuged at 17,000 × g for 10 min at 4 °C, insol-
uble pellets were discarded, and protein concentration was determined using the Pierce protein assay (PN22660).
Lysates of equal protein concentration were separated by SDS-PAGE, transferred onto a PVDF membrane 
and blocked for 1 h in Tris-buffered saline (150 mM NaCl, 20 mM Tris-HCl, pH 7.6) with 0.1% (v/v) Tween-20, 
Figure 4. Proposed role for GPR21 in the development of type 2 diabetes. The constitutively active GPR21 
recruits and activates Gα 15/16, which facilitates the hydrolysis of PIP2 into DAG and IP3 through the action of 
PLC. Both DAG and IP3 activate PKC, which signals to and activates the MAPK cascade. The MAPK JNK plays 
a crucial role in the development of insulin resistance as it promotes the phosphorylation of a key component 
of the insulin signalling cascade, IRS1, at Ser307, thereby preventing insulin-induced tyrosine phosphorylation 
of this protein. GPR21-induced activation of the MAPKs may contribute to the development of type 2 diabetes. 
Due to the potential of a native inverse agonist in serum, GPR21 signal transduction is believed to be tightly 
regulated under normal physiological conditions. However in a state of obesity, elevated GPR21 activity may 
become deleterious, potentially promoting the genesis of insulin resistance.
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containing 5% (w/v) bovine serum albumin (BSA). Membranes were incubated with primary antibodies over-
night at 4 °C followed by the secondary antibodies conjugated with horseradish peroxidase for 2 h at room temper-
ature. Protein bands were visualised on x-ray film with enhanced chemiluminescence (Roche). Immunodetection 
was achieved using the following antibodies from Cell Signaling Technology; phospho-PKCδ Thr505 (9374), 
phospho-Erk Thr202/Tyr204 (4370), Erk (4695), phospho-p38 Thr180/Tyr182 (4511), p38 (9212), phospho-JNK 
Thr183/Tyr185 (4668), JNK (9258), phospho-Insulin Receptor β Tyr1150/1151 (3024), IRS1 (3407), phospho-Akt Ser473 
(9271), Akt (9272), phospho-AS160 Thr642 (8881), phospho-AS160 Ser588 (8730), AS160 (2670) and myc (2276). 
Phospho-IRS1 Tyr612 (44-816G) was supplied by Life Technologies and Insulin Receptor β (ab69508), GPR21 
(ab139654), F4/80 (ab74383) and β -actin (ab8226) were purchased from Abcam.
2-deoxyglucose uptake. Glucose uptake was measured according to Yun and colleagues18, with modifica-
tions. Transfected HEK293T cells were washed once with KRB warmed to 37 °C, then incubated with 1 μ Ci/ml 
[3H]-2-deoxyglucose (PerkinElmer, NET328A001MC), prepared in KRB, at 37 °C for 10 min. To terminate the 
assay, cells were washed 3 times with ice-cold KRB and lysed in 0.1% (w/v) SDS at 37 °C for 30 min. Cell lysates 
were diluted 1:4 in β -scintillation fluid (Beta-Plate Scint, PerkinElmer). Incorporation of [3H]-2-deoxyglucose 
was quantified with a Wallac 1450 Microbeta Liquid Scintillation Counter (PerkinElmer), expressing results in 
counts per minute (CPM). Total protein contents were determined by the Bicinchoninic Acid procedure19 to 
define results as CPM/mg.
GPR21 homology modelling and ligand docking. An in-house GPR21 structural model was con-
structed using the Modeller software embedded in Biovia Discovery Studio20. A sequence alignment was con-
structed between the amino acid sequence of the GPCR templates (2RH121, 4GBR22), with the hGPR21 (Swissprot 
accession code Q99679), and manually inspected to confirm the correct alignment of conserved residues23. Using 
the alignment, 1,000 different models were generated with a subsequent refinement protocol applied to the loop 
regions24,25. Disulfide bonds were formed between Cys102 and Cys181. The final model was selected using the 
Modeller objective score and a selection of protein assessment tools (http://services.mbi.ucla.edu/SAVES/)26,27.
Utilising this developed protein model, virtual screening processes were implemented to examine large com-
pound databases (e.g. Specs, www.specs.net) in silico through molecular docking studies (OpenEye, Fred28–30). 
The molecules were standardised, and tautomers and stereoisomers were enumerated using Biovia Pipeline 
Pilot20. Conformers were generated using Omega31–33 from Openeye prior to docking using default parameters 
with Fred29 and scoring with the chemgauss3 scoring function. From the ranked list, 11 compounds were ordered 
for experimental validation.
Data analysis. Data are presented as means ± standard error of the mean (SEM). The unpaired Student’s 
t-test was used to determine significance between groups. One-way analysis of variance (ANOVA) with a 
post-hoc Tukey test was used to determine significance among three or more groups. Significance was denoted as 
p < 0.05* , p < 0.01**, p < 0.001***.
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